James V. Ellard
Directeur Général chez New England Biolabs (UK) Ltd.
Profil
James V.
Ellard has held multiple positions throughout his career.
Currently, he is the Chief Executive Officer & Director at New England Biolabs (UK) Ltd.
since 1984.
He is also the Chairman at New England Biolabs, Inc. since 2022.
Additionally, he serves as a Trustee at the Institution for Savings in Newburyport & Its Vicinity.
Mr. Ellard completed his undergraduate degree at the Massachusetts Institute of Technology.
Postes actifs de James V. Ellard
| Sociétés | Poste | Début |
|---|---|---|
New England Biolabs, Inc.
 New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | Président | - |
Institution for Savings in Newburyport & Its Vicinity
 Institution for Savings in Newburyport & Its Vicinity Regional BanksFinance Institution for Savings in Newburyport & Its Vicinity provides banking services. It offers personal, business and commercial banking services. The company was founded in 1820 and is headquartered in Newburyport, MA. | Directeur/Membre du Conseil | - |
New England Biolabs (UK) Ltd.
 New England Biolabs (UK) Ltd. Medical SpecialtiesHealth Technology Part of New England Biolabs, Inc., New England Biolabs (UK) Ltd. is a British company that provides molecular biology reagents and technical support. The company is based in Hitchin, UK. The company offers a range of products including restriction enzymes, polymerases, competent cells, and sample prep for NGS. Additionally, they provide endoglycosidases, exoglycosidases, and heparinases for glycobiology research. Founded in 1993, James V. Ellard has been the CEO of the company since 1984. | Directeur Général | 01/01/1984 |
Formation de James V. Ellard
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
New England Biolabs, Inc.
New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | Process Industries |
Institution for Savings in Newburyport & Its Vicinity
Institution for Savings in Newburyport & Its Vicinity Regional BanksFinance Institution for Savings in Newburyport & Its Vicinity provides banking services. It offers personal, business and commercial banking services. The company was founded in 1820 and is headquartered in Newburyport, MA. | Finance |
New England Biolabs (UK) Ltd.
New England Biolabs (UK) Ltd. Medical SpecialtiesHealth Technology Part of New England Biolabs, Inc., New England Biolabs (UK) Ltd. is a British company that provides molecular biology reagents and technical support. The company is based in Hitchin, UK. The company offers a range of products including restriction enzymes, polymerases, competent cells, and sample prep for NGS. Additionally, they provide endoglycosidases, exoglycosidases, and heparinases for glycobiology research. Founded in 1993, James V. Ellard has been the CEO of the company since 1984. | Health Technology |
